Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein

Alaa T. Alshareeda(King Abdulaziz Medical City), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Ola H. Negm(University of Nottingham), Patrick J. TigHhe(University of Nottingham), Ian O. Ellis(University of Nottingham), Andrew R. Green(Nottingham Biomedical Research Centre), Mohammed A. Aleskandarany(Nottingham University Hospitals NHS Trust), Christopher C. Nolan(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Breast Cancer Research and Treatment
July 27, 2016
10.1007/s10549-016-3915-8
Cited by 43

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Clinical and genetic characteristics of hereditary pancreatitis in Europe
|Clinical Gastroenterology and Hepatology|2004|615